Daniel Klamer

Craft the strategic business case (scientific and commercial) for new drug development initiatives, guide the multi-stage commercialization process and lead the sourcing and assessment of new market opportunities, possible acquisitions, and partnerships. Played role in developing the company to its current position, with multiple late-stage assets with the potential to treat several neurodegenerative and neurodevelopmental diseases. A key member of the Management Team. • Repeatedly spearhead process to identify potential diseases and target populations, conduct competitive and market analysis, and guide drug development from pre-clinical proof of concept to commercialization • Assess new, competitive, and potentially synergistic therapeutic compounds or devices • Developed a structured, efficient process and lead detailed due diligence on potential deals • Present at investor and scientific conferences

Joined as 3rd employee, playing a vital role in the company’s initial growth and pipeline development

Supervise multiple doctoral and master’s-level pre-clinical and clinical research projects • Developing preclinical hypotheses to clinical proof-of-concept studies • Lead international seminars and successfully obtained major research funding grants

• Hired and built effective, cross-functional team of experts in business development and marketing, intellectual property law and operations • Attracted critical new investors and partners • Negotiated major investment to commercialize Eidisine™ including significant financing by venture capital

Played central role in identifying strategic buying and partnering opportunities within a tight timeframe • Created product and company financial models and scenario assessments, and performed due diligence • Contributed to deal negotiations and execution • Identified and evaluated companies/products for orphan indications in e.g. liver, kidney and CNS • Analyzed the competitive drug landscape from both financial and scientific perspective

Led development of product pipeline and out-licensing. Developed, managed and communicated integrated project plans to partners and CROs.

Led and evaluated multiple discovery-phase neuropharmacological research products with a focus on strategic evaluation at preclinical and clinical stages for development and commercialization. Managed teams of up to 15 people, from technicians to Ph.D. level. Led key projects for transitioning discovery phase substances into candidate drugs; crafted and sold business case and obtained critical financing for development.

Investigated cognitive impairments in psychiatric diseases.

Investigated neuronal synchronization in order to identify cognitive processes. Participated in the course “Learning to mentor a new generation of scientists” and workshops for “Preparing future science faculty”.

Special competence in in-vivo pharmacology and behavioral models assessing cognitive processes Course director in Basic and Applied Pharmacology for the Programme in Biomedical Laboratory Science, 2003, 2004, 2008 & 2009 Lecturer for medical students, the Dentist Programme, the Programme in Biomedical Laboratory Science and the Study Programme for Prescriptionists, in ”schizophrenia and psychosis,” “dementia and stroke,” “antihistamines” and “depression and mania” in the Basic and Applied Pharmacology course, 2001-2005 & 2007-2009 Supervised M.Sc. students in their thesis work